VaxHit also enables the identification of vaccines against selected intracellular pathogens. Vaxil is developing a Tuberculosis vaccine – MTBuVax™. This is a multi-antigenic, multi-epitopes subunit vaccine with epitopes derived from the SP domains of up to 5 known and novel MTb antigens. MTBuVax has already manifested superior immunity in a large number of blood samples derived from healthy individual and patient with active TB comparing to known peptide vaccines from the same antigens. It also performed robust cellular and humoral immunogenicity in mice.Click below to read more